Overview
The aim of the study is to evaluate the impact of turmeric and pentoxiphylline on serum levels of protein-bound uremic toxin (p-cresyl sulfate), oxidative stress biomarker level (Malonaldehyde), inflammatory biomarker level (Highly sensitive C-reactive protein). In addition to the evaluation of its effect on metabolic profile and disease progression in chronic kidney disease patients.
Description
- Ethical committee approval has been obtained from Ethics committee of Faculty of Medicine, Alexandria University.
- All participants should agree to take part in this clinical study and will provide informed consent.
- Sixty chronic kidney disease patients will be recruited from the Kidney and Urology Center (KUC) and Alexandria main university hospital (AMUH).
The 60 participants will be randomly assigned into 3 arms.
Group 1 (Control group; n=20): Patients will be treated with standard care only for 6 months. Group 2 (n=20): Patients will be treated with the same standard care plus curcumin capsules 500 mg twice daily for 6 months. Group 3 (n=20): Patients will be treated with the same standard care plus pentoxiphylline 400 mg twice daily for 6 months.
4. All patients will be submitted to :
Full patient history and clinical examination. Blood withdrawal in order to conduct lab work.
5. Patients demographic data will be recorded with respect to age, weight and other co-morbidities.
6. Statistical tests appropriate to the study design will be conducted to evaluate the significance of the results.
7. Results, conclusion, discussion and recommendations will be given.
Eligibility
Inclusion Criteria:
- Age ≥ 18 years old.
- Both sexes.
- Non-hemodialysis CKD patients (Stage III -V)
- Patients matched in the duration of CKD.
- Patients with albumin-to-creatinine ratio ≥ 30 mg/g.
- Patients with serum Potassium < 5 mEq/L
Exclusion Criteria:
- Patients with elevated level of potassium ≥ 5 mEq/L.
- Patients with cancer.
- Patients with kidney stones and urinary tract infection.
- Patients with bleeding disorder.
- History of drug allergy to study medications.
- Pregnant and breastfeeding women.
